Diplomat ranks third among private healthcare companies in Inc. 5000 list
FLINT, Mich. — Diplomat Specialty Pharmacy has made Inc. magazine’s list of the top 5,000 fastest-growing private companies in the United States for the fifth consecutive year, ranking third in the healthcare field, the company said Wednesday.
"Recognition on the Inc. 5000 list continues to be an important metric in gauging our overall growth," Diplomat CEO Phil Hagerman said. "What is especially meaningful to the Diplomat team is we continue to grow the business and forge relationships with new healthcare industry partners while achieving sustained customer and physician satisfaction rates above 98%."
The company created 500 jobs in the Flint, Mich., area between 2009 and 2012 and was cited by Inc. in December 2012 as one of the country’s top 100 job creators.
"Diplomat remains on track to add a total of 1,000 new jobs between 2010 and 2015," Hagerman said. "We’ll need that increased capacity as projected specialty pharmacy purchases are projected to be 50% of the total drug spend by 2018."
Hagerman cited the company’s attention to patient care and adherence.
"The key to optimal patient compliance and adherence lies with patient education and training, packaging that keeps drugs safe and secure, yet is easy for patients to open, side-effect management kits, nurse adherence calls for clinical support and guidance and adaptive technology, whether that be through smartphones, prescription bottles with glow caps or packing with alarms and reminders," Hagerman said. "Diplomat is a leader in these areas, and we will continue to focus efforts on new approaches to compliance and adherence through our high-tech, high-touch patient strategy."
Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.
Entera Health launches EnteraGam
CARY, N.C. — Entera Health has launched a new prescription medical food product for patients with intestinal disorders, the company said.
The drug maker announced the availability of EnteraGam (serum-derived bovine immunoglobulin protein isolate, SBI) for patients with chronic loose or frequent stools due to irritable bowel syndrome or HIV. The drug is meant to treat patients who have limited or impaired ability to ingest, digest, absorb or metabolize ordinary foodstuffs or certain nutrients.
The company is offering a savings program allowing insured patients to pay as little as $25 for their prescriptions. The program will be available in more than 40,000 pharmacies, the company said.
FlavoRx, RxNT integrate medicine flavoring with e-prescribing, electronic health record applications
COLUMBIA, Md. — RxNT’s e-prescribing and electronic health record systems will incorporate taste options recommended by FlavoRx for liquid medications given to children in order to promote medication adherence, the two companies said.
In a recently announced deal, the companies said they would make enhancing the taste of medicine a seamless option for pediatric prescriptions and their patients. Prescribers can use RxNT’s software to designate a child’s preferred medication flavor directly on the electronic prescription, sending it to the pharmacy and facilitating the custom-flavoring process. Studies have indicated that bad-tasting medications can be a barrier to adherence among children.
"Pediatricians, nurse practitioners and physician’s assistants know first-hand the importance of taste when it comes to pediatric adherence," FlavoRx CEO Stuart Amos said. "The FlavoRx partnership with RxNT will go a long way toward improving adherence and outcomes for patients whose doctors, nurse practitioners or physician’s assistants use the RxNT eRx or RxNT EHR systems."